mdlinx mdlinx
Latest (115) Full Text Articles (6313) Focus on Dermatologic Article Summary

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly
The Lancet Oncology,  Clinical Article

Wick W et al. – Temozolomide alone is non–inferior to radiotherapy alone in the treatment of elderly patients with malignant astrocytoma. MGMT promoter methylation seems to be a useful biomarker for outcomes by treatment and could aid decision–making.

Methods
  • Between May 15, 2005, and Nov 2, 2009, the authors enrolled patients with confirmed anaplastic astrocytoma or glioblastoma, age older than 65years, and a Karnofsky performance score of 60 or higher.
  • Patients were randomly assigned 100mg/m2 temozolomide, given on days 1-7 of 1week on, 1week off cycles, or radiotherapy of 60.0Gy, administered over 6-7weeks in 30 fractions of 1.8-2.0Gy.
  • The primary endpoint was overall survival.
  • They assessed non-inferiority with a 25% margin, analysed for all patients who received at least one dose of assigned treatment.

Results
  • Of 584 patients screened, the authors enrolled 412.
  • 373 patients (195 randomly allocated to the temozolomide group and 178 to the radiotherapy group) received at least one dose of treatment and were included in efficacy analyses.
  • Median overall survival was 8.6months (95% CI 7.3-10.2) in the temozolomide group versus 9.6months (8.2-10.8) in the radiotherapy group (hazard ratio [HR] 1.09, 95% CI 0.84-1.42, pnon-inferiority=0.033).
  • Median event-free survival (EFS) did not differ significantly between the temozolomide and radiotherapy groups (3.3months [95% CI 3.2-4.1] vs 4.7 [4.2-5.2]; HR 1.15, 95% CI 0.92-1.43, pnon-inferiority=0.043).
  • Tumour MGMT promoter methylation was seen in 73 (35%) of 209 patients tested.
  • MGMT promoter methylation was associated with longer overall survival than was unmethylated status (11.9months [95% CI 9.0 to not reached] vs 8.2months [7.0-10.0]; HR 0.62, 95% CI 0.42-0.91, p=0.014).
  • EFS was longer in patients with MGMT promoter methylation who received temozolomide than in those who underwent radiotherapy (8.4months [95e% CI 5.5—11.7] vs 4.6 [4.2—5.0]), whereas the opposite was true for patients with no methylation of the MGMT promoter (3.3 months [3.0-3.5] vs 4.6months [3.7-6.3]).
  • The most frequent grade 3-4 intervention-related adverse events were neutropenia (16 patients in the temozolomide group vs two in the radiotherapy group), lymphocytopenia (46 vs one), thrombocytopenia (14 vs four), raised liver-enzyme concentrations (30 vs 16), infections (35 vs 23), and thromboembolic events (24 vs eight).

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

Last month's top read Top Articles of 2013

1 Coffee intake and gastric cancer risk Cancer Epidemiology, Biomarkers & Prevention, March 20, 2014    Clinical Article

2 Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial The Lancet Oncology, March 7, 2014    Clinical Article

3 Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial The Lancet Oncology, March 11, 2014    Clinical Article

4 Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials The Lancet, March 25, 2014    Evidence Based Medicine    Clinical Article

5 Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): A companion analysis of a randomised controlled trial The Lancet Oncology, March 14, 2014    Clinical Article

6 Chemoradiation therapy versus chemotherapy alone for gastric cancer after R0 surgical resection: A meta-analysis of randomized trials Oncology, February 4, 2014    Evidence Based Medicine    Clinical Article

7 Risk of developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation Journal of the National Cancer Institute, March 4, 2014    Clinical Article

8 Screening for prostate cancer with the prostate-specific antigen test: A review of current evidence JAMA, March 21, 2014    Evidence Based Medicine    Clinical Article

9 Dietary carrot consumption and the risk of prostate cancer European Journal of Nutrition, February 17, 2014    Clinical Article

10 Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: A meta-analysis of individual patient data The Lancet Oncology, March 7, 2014    Clinical Article

11 A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients Annals of Oncology, February 18, 2014    Clinical Article

12 Radical prostatectomy or watchful waiting in early prostate cancer New England Journal of Medicine, March 10, 2014    Evidence Based Medicine    Clinical Article

13 Coffee consumption and prostate cancer risk: An updated meta-analysis Cancer Causes and Control, March 4, 2014    Evidence Based Medicine    Clinical Article

14 Statins and aspirin for chemoprevention in Barrett's esophagus: Results of a cost-effectiveness analysis Cancer Prevention Research, February 25, 2014    Clinical Article

15 Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort The Lancet Oncology, March 24, 2014    Clinical Article

16 Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab Journal of Clinical Oncology, March 19, 2014    Clinical Article

17 Tea consumption and leukemia risk: A meta-analysis Tumor Biology, February 13, 2014    Evidence Based Medicine    Clinical Article

18 Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study The Lancet Oncology, March 3, 2014    Clinical Article

19 Yoga’s impact on inflammation, mood, and fatigue in breast cancer survivors: a randomized controlled trial Journal of Clinical Oncology, February 3, 2014    Clinical Article

20 Tumor infiltrating lymphocytes is prognostic and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial Annals of Oncology, March 12, 2014    Clinical Article

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore

Other Topics in Oncology

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow
Like

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close